{"result": "(\"entity\"<|>MANOLITSAS T.<|>PERSON<|>Manolitsas T. is an author referenced in the context of medical research related to chylothorax and its treatment.)\n##\n(\"entity\"<|>ABDESSELAM S.<|>PERSON<|>Abdessalam S. is an author referenced in the context of medical research related to chylothorax and its treatment.)\n##\n(\"entity\"<|>FOWLER J M.<|>PERSON<|>Fowler J M. is an author referenced in the context of medical research related to chylothorax and its treatment.)\n##\n(\"entity\"<|>GYNECOLOGIC MALIGNANCIES<|>EVENT<|>Gynecologic malignancies are medical conditions discussed in the context of chylothorax treatment.)\n##\n(\"entity\"<|>CHYLOTHORAX<|>EVENT<|>Chylothorax is a medical condition involving lymphatic fluid accumulation in the pleural cavity, discussed in various treatment contexts.)\n##\n(\"entity\"<|>MAYO CLINIC<|>ORGANIZATION<|>Mayo Clinic is a medical institution referenced in the context of research on pleural liquid characteristics of chylothorax.)\n##\n(\"entity\"<|>EUROPEAN JOURNAL OF CARDIOTHORACIC SURGERY<|>ORGANIZATION<|>European Journal of Cardiothoracic Surgery is a publication that features research on the management of chylothorax.)\n##\n(\"entity\"<|>NUTRITION<|>EVENT<|>Nutrition is a key aspect discussed in the context of managing chylothorax and supporting patients with chyle leaks.)\n##\n(\"relationship\"<|>MANOLITSAS T.<|>GYNECOLOGIC MALIGNANCIES<|>Manolitsas T. authored a study related to chylothorax following treatment for gynecologic malignancies<|>7)\n##\n(\"relationship\"<|>ABDESSELAM S.<|>GYNECOLOGIC MALIGNANCIES<|>Abdessalam S. authored a study related to chylothorax following treatment for gynecologic malignancies<|>7)\n##\n(\"relationship\"<|>FOWLER J M.<|>GYNECOLOGIC MALIGNANCIES<|>Fowler J M. authored a study related to chylothorax following treatment for gynecologic malignancies<|>7)\n##\n(\"relationship\"<|>CHYLOTHORAX<|>MAYO CLINIC<|>Mayo Clinic conducted research on pleural liquid characteristics of chylothorax<|>8)\n##\n(\"relationship\"<|>CHYLOTHORAX<|>EUROPEAN JOURNAL OF CARDIOTHORACIC SURGERY<|>Research on the management of chylothorax is published in the European Journal of Cardiothoracic Surgery<|>8)\n##\n(\"relationship\"<|>CHYLOTHORAX<|>NUTRITION<|>Nutrition is an important aspect of managing chylothorax and supporting patients<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 90-95%                     tratamiento de estas entidades será inicialmente conser-\ncuando el conducto torácico puede ser identificado.                             vador basado en una dieta modificada en TCL, con res-\n   Otros tratamientos quirúrgicos con carácter paliativo                        tricción de la grasa hasta un 20% del contenido energé-\nson el talcaje pleural o el shunt pleuroperitoneal en el                        tico de la dieta y suplementada con TCM. Además de la\n---\n 362      BLOQUE: LÍPIDOS\n\n\n\nsuplementación        con    TCM,    se   puede     incrementar     el  15.  Manolitsas T. P, Abdessalam S, Fowler J M. Chy-\naporte energético con fórmulas nutricionales exentas de                      lous ascites following treatment for gynecologic\ngrasa. Este tratamiento puede mantenerse durante 1-2                         malignancies. Gynecol Oncol 2002; 86:370-374.\nsemanas y, en caso de no resolución, se optará por la                   16.  Yol S, Bostanci E B, Ozoguil Y, Ulas M, Akoglu M.\nNP. La somatostatina y la octreotida administradas en                        A rare complication of D3 dissection for gastric\ninfusión continua o por vía subcutánea en combinación                        carcinoma:        chyloperitoneum.          Gastric     Cancer\ncon dieta modificada con TCM o con NP forman parte                           2005; 8:35-38.\ndel tratamiento conservador y pueden contribuir a la re-                17.  Skouras V, Kalomenidis I. Chylothorax: diagnosis\nsolución de los casos, especialmente en aquellos casos                       approach. Curr Opin Pulm Med 2010; 16: 387-93.\ncon pérdidas inferiores a 1.000 ml/día.                                 18.  Maldonado F, Hawkins FJ, Daniels CE, Doerr CH,\n   El tratamiento quirúrgico o con radiología interven-                      Decker PA, Ryu JH. Pleural liquid charactyeristics of\ncionista se reservará para los casos refractarios al trata-                  chylothorax. Mayo Clinic Proc 2009; 84: 1243-45.\nmiento conservador, especialmente en los casos de                       19.  Agrawal V, Doleken P,Shan SA. Pleural liquid anal-\nquilotórax o ascitis quilosa postraumáticas y con fístu-                     ysis   in  chylous     pleural    effusion.     Chest    2008;\nlas de alto débito.                                                          133:1436-1441.\n                                                                        20.  Bender B, Murthy V, Chamberlain RS. The chang-\n7.   Bibliografía                                                            ing management of chylothorax in the modern\n                                                                             era. Eur J Cardiothorax Surg 2016; 49:18-24.\n  1.  Merrigan BA, Winter DC, O’Sullivan. Chylothorax.                  21.  Sriram K, Meguid RA, Meguid MM. Nutritional\n      Br J Surg 1997; 84: 15-20.                                             support     in  adults    chyle    leaks.  Nutrition     2016;\n  2.  Riquet M, Le Pimpec Barthes F, Badia A. Le Chylo-                      32:281-286.\n      thorax. Presse Medicale 2002; 31:548-55.                          22.  Sapin DA, Mc Clave SA. Chylothorax and Chylous\n  3.  Aalami O.O, Allen dB, Organ C.H. Chylous ascites:                      Ascites. En: Gottschlich MM, De Legge MH, Mat-\n      A collective review. Surgery 2000; 128:761-778.                        tox T, Mueller C, Worthington P.The ASPEN Nutri-\n  4.  Nair S. K, Petko M, Hayward M. P. Aetiology and                        tion Support Core Curriculum. A case-based ap-\n      management of chylothorax in adults. Eur J Cardi-                      proach – the adult patient. Silver Spring,MD 2007;\n      otoracic Surg 2007; 32:362-369.                                        477-486.\n  5.  Smoke A, De Legge MH. Chyle leaks: Consensus on                   23.  Schild HH, Strassburg CP, Welz A, Kalff J. Treat-\n      management? Nutr Clin Pract 2008; 23:529-532.                          ment options in patients with chylothorax. Dtsch\n  6.  de Gier H.W, Balm A.J.M, Bruning P.F, Gregor T,                        Arztebl Int 2013; 110:819-26.\n      Hilgers F.J.M. Systematic aproach to the teatment                 24.  Weniger M, D’Haese JG, Angele MK, Kleespies A,\n      of chylous leakage after neck dissection. Head &                       Werner J, Hartwig W. Treatment options for chy-\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}